Practical Pharmacology for Alzheimer’s Disease

The wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer’s disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. However, the fact that clinical trials of these drugs have not yet yielded satisfactory resu...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Kudo, Takashi (Συγγραφέας), Davis, Kenneth L. (Συγγραφέας), Blesa Gonzalez, Rafael (Συγγραφέας), Wilkinson, David George (Συγγραφέας)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2016.
Έκδοση:1st ed. 2016.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 02874nam a22005055i 4500
001 978-3-319-26206-2
003 DE-He213
005 20160211151041.0
007 cr nn 008mamaa
008 160210s2016 gw | s |||| 0|eng d
020 |a 9783319262062  |9 978-3-319-26206-2 
024 7 |a 10.1007/978-3-319-26206-2  |2 doi 
040 |d GrThAP 
050 4 |a RM315-334 
072 7 |a MMGW  |2 bicssc 
072 7 |a MED105020  |2 bisacsh 
082 0 4 |a 615.78  |2 23 
100 1 |a Kudo, Takashi.  |e author. 
245 1 0 |a Practical Pharmacology for Alzheimer’s Disease  |h [electronic resource] /  |c by Takashi Kudo, Kenneth L. Davis, Rafael Blesa Gonzalez, David George Wilkinson. 
250 |a 1st ed. 2016. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2016. 
300 |a VIII, 141 p. 27 illus., 9 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 |a Basic theory of pharmacology for Alzheimer’s disease -- Practical Pharmacology of Donepezil -- Practical pharmacology of Galantamine -- Practical pharmacology of Rivastigmine -- Practical Pharmacology of Memantine -- How do we use Symptomatic drugs for Dementia. 
520 |a The wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer’s disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. However, the fact that clinical trials of these drugs have not yet yielded satisfactory results has meant that for the time being patients continue to be treated only with symptomatic drugs. Currently, four such drugs are available: donepezil, galantamine, rivastigmine, and memantine. In this book, the four leading experts on each of these drugs explain their practical pharmacology with the aim of providing a sound basis for their use, which to date has been of questionable proficiency. In addition, an introductory chapter considers the basic theory of pharmacology for Alzheimer’s disease and the book closes with an overview of the ways in which symptomatic drugs are used for dementia. 
650 0 |a Medicine. 
650 0 |a Neurology. 
650 0 |a Psychopharmacology. 
650 0 |a Pharmacotherapy. 
650 1 4 |a Medicine & Public Health. 
650 2 4 |a Psychopharmacology. 
650 2 4 |a Neurology. 
650 2 4 |a Pharmacotherapy. 
700 1 |a Davis, Kenneth L.  |e author. 
700 1 |a Blesa Gonzalez, Rafael.  |e author. 
700 1 |a Wilkinson, David George.  |e author. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783319262048 
856 4 0 |u http://dx.doi.org/10.1007/978-3-319-26206-2  |z Full Text via HEAL-Link 
912 |a ZDB-2-SME 
950 |a Medicine (Springer-11650)